$SRDX (SurModics, Inc.)

$SRDX {{ '2016-01-11T16:04:08+0000' | timeago}} • Announcement

$SRDX acquired NorMedix for $14MM, including an upfront payment of $7MM, and up to $7MM based on the achievement of revenue and other value-creating milestones through Sept. 30, 2019. Other financial terms of the agreement were not disclosed.

$AMGN {{ '2018-01-19T13:28:13+0000' | timeago}} • Announcement

The European Commission (EC) has granted marketing authorization for MVASI from $AMGN and $AGN. MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers.

$AGN {{ '2018-01-17T13:14:16+0000' | timeago}} • Announcement

$AGN and $IRWD reached an agreement with Indian pharma company Sun Pharma to resolve a patent litigation for the generic version of constipation drug Linzess in the U.S. As per the agreement, Sun Pharma will be able to market the generic version of Linzess in the U.S. from Feb. 1, 2031. All the litigations related to Linzess were dismissed.

$SYK {{ '2018-01-09T17:21:37+0000' | timeago}} • Announcement

$SYK said that for 4Q17 its preliminary results are of net sales growth of 10% to $3.5Bil, while for FY17, its net sales grew 9.9% to $12.4Bil. Excluding the impact of foreign currency & acquisitions, net sales rose 8.1% and 7.1% in 4Q17 and FY17. For 2018, $SYK expects modest headwinds that will be manageable within its overall financial targets.

$HRC {{ '2018-01-09T17:07:14+0000' | timeago}} • Announcement

$HRC announced its preliminary 1Q18 revenue. For this period, the company expects worldwide revenue of approx $670MM, an increase of 5% YoY. Core revenue increased approx 2%, exceeding the company's previously issued guidance of flat core revenue growth.

$AGN {{ '2018-01-09T15:46:35+0000' | timeago}} • Announcement

$AGN, which announced its plan to give pink slips to 1,000 of its employees and cut down 400 open positions earlier this year, provided FY18 financial outlook. In 2018, Allergan plans to sell its remaining position of 10% stake in $TEVA through Forward Sale Agreements and/or open market sales.

$TFX {{ '2018-01-02T14:56:01+0000' | timeago}} • Announcement

$TFX completed its senior leadership transition. Effective Jan. 1, 2018, Liam Kelly, who was previously President & COO, assumed the position of President & CEO. Mr. Kelly succeeds Benson Smith, who retired as CEO, effective Dec. 31, 2017. Mr. Smith will continue to serve as non-executive Chairman of the Board.

$AGN {{ '2017-12-26T12:22:55+0000' | timeago}} • Announcement

$AGN said that the Federal Circuit confirmed that a proposed generic version of Combigan eye drug from Sandoz, a unit of $NVS, did not infringe Allergan's two patents. The Federal Circuit also reversed the district court's decision that Sandoz's proposed generic product infringes Allergan's 3rd patent. Allergan plans to file for rehearing within 30 days.

$AGN {{ '2017-12-21T14:38:43+0000' | timeago}} • Announcement

$AGN and its partner $PRTK announced that FDA accepted to review Seysara, an investigational drug for treating acne. Allergan, which has the U.S. rights of developing and marketing Seysara, expects FDA to take action on this in 2H18. Paratek retains the non-U.S. rights. In March 2017, Allergan announced positive results from Seysara Phase 3 trials.

$AGN {{ '2017-12-18T22:26:29+0000' | timeago}} • Announcement

Robert Stewart, COO of $AGN will resign from his role. He has been named as the CEO of the newly formed Amneal Pharmaceuticals, effective Jan. 25, 2018. Following Rob's departure, Wayne Swanton, SVP, Global Operations has been promoted as EVP, Global Operations of Allergan.

$AGN {{ '2017-12-18T22:14:14+0000' | timeago}} • Announcement

$AGN and its development partner Gedeon Richter Plc reported positive results from phase 3 study of cariprazine, which is used to treat the bipolar depression. Allergan plans to file the New Drug Application to the FDA in 2H18.

$IPXL {{ '2017-12-18T13:05:53+0000' | timeago}} • Announcement

Amneal Pharmaceuticals LLC and $IPXL said Robert Stewart will join Amneal as President, effective Jan. 25, 2018. Stewart most recently served as COO of $AGN. After completion of combination of Amneal and $IPXL, Stewart will become President and CEO of the combined company, to be named Amneal Pharmaceuticals Inc., and will become a BoD member.

$REGN {{ '2017-12-18T12:38:12+0000' | timeago}} • Announcement

$REGN and ISA Pharmaceuticals announced a clinical collaboration to advance ISA101, an immunotherapy targeting human papillomavirus type 16-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. $REGN and ISA will jointly conduct trials of treatment in cervical cancer and head-and-neck cancer.

$AGN {{ '2017-12-12T19:58:45+0000' | timeago}} • Announcement

$AGN gets FDA clearance for the CoolSculpting, a treatment to improve the appearance of lax tissue in double chin. Allergan got this CoolSculpting technology by acquiring Zeltiq Aesthetics in Feb. 2017 for $2.4Bil. Allergan added that in an 18-week study, 77% of patients showed improved appearance in their lax tissue.

$AGN {{ '2017-12-12T19:07:05+0000' | timeago}} • Announcement

$AGN enters into a buyout deal with $RPRX through a cash tender offer of $0.67 per share, representing a 43% premium of Repros Therapeutics’ Dec. 11th closing price ($0.47). Allergan's subsidiary will acquire Repros, which focuses on developing the drugs for male and female reproductive disorders. The deal is expected to close in 1Q18.

$TFX {{ '2017-12-12T15:30:39+0000' | timeago}} • Announcement

$TFX's respiratory division has signed a new group purchasing agreement with HealthTrust. The Respiratory Heaters & Accessories agreement which became effective Dec. 1, 2017, covers Teleflex's full line of Active Humidification, Non Invasive Ventilation (NIV), and High Flow Nasal Cannula Therapy (HFNCT) products.

$SYK {{ '2017-12-12T14:28:46+0000' | timeago}} • Announcement

$SYK said Howard Cox Jr. has notified the company that he will not stand for re-election at Stryker's 2018 Annual Meeting, which is expected to be held on May 2, 2018. In light of Cox's immense contributions to the company, he will be named Director Emeritus.

$HLS {{ '2017-12-12T13:23:46+0000' | timeago}} • Announcement

$HLS appointed Nancy Schlichting as an independent director, effective Dec. 11, 2017. With this appointment, the Board will expand to 11 directors. Schlichting currently serves on the boards of $WBA and $HRC.

$SYK {{ '2017-12-11T21:53:53+0000' | timeago}} • Announcement

$SYK said that the simplified public tender offer for the shares and BSAAR warrants of VEXIM has closed. $SYK, which already owned over 50% of the share capital and voting rights of VEXIM, acquired an additional 4.04MM shares during the offer period, as well as 226,520 BSAAR warrants that it has exercised for new shares of VEXIM.

$ENTL {{ '2017-12-08T17:39:22+0000' | timeago}} • Announcement

Rowley Law PLLC is investigating potential claims against $ENTL and its BoD for breach of fiduciary duty concerning the proposed acquisition of the company by $SYK. Stockholders will receive $24.00 in cash for each share of $ENTL that they hold. The transaction is valued at about $662MM.

$SYK {{ '2017-12-07T16:33:56+0000' | timeago}} • Announcement

$SYK agreed to buy $ENTL for $24 per share, or an equity value of about $662MM. The transaction is expected to be dilutive to $SYK's 2018 adjusted EPS by about $0.04 and accretive thereafter. Guggenheim Securities served as financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP served as outside legal counsel for $SYK.

Recent Transcripts

RAD (Rite Aid Corporation)
Wednesday, January 3 2018 - 10:00pm
ONVO (Organovo Holdings, Inc.)
Thursday, November 9 2017 - 10:00pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
GMED (Globus Medical, Inc.)
Wednesday, November 8 2017 - 10:30pm
SRDX (SurModics, Inc.)
Wednesday, November 8 2017 - 1:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
RAD (Rite Aid Corporation)
Thursday, September 28 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm

AlphaGraphics you may like